drugset / Trial / NCT02464670

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

NCT02464670

RandomizedSequentialDouble-blindPrevention

Summary

This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.

Timeline

Start
2015-05
Primary completion
2018-05-24
Completion
2018-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject INO-4201 Vaccine 0.8 mg Intramuscular
Subject INO-4201 Vaccine 1 mg Intramuscular
Subject INO-4201 Vaccine 1.6 mg Intramuscular
Subject INO-4201 Vaccine 2 mg Intramuscular
Subject INO-4202 Vaccine 2 mg Intramuscular
Subject INO-4212 Vaccine 4 mg Intramuscular
Subject Rocakinogene Sifuplasmid Vaccine 0.2 mg Intramuscular
Subject Rocakinogene Sifuplasmid Vaccine 0.4 mg Intramuscular
Subject Rocakinogene Sifuplasmid Vaccine 1 mg Intramuscular